HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE COVER ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a letter to the editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brawer, M. K. Search for Related Content PubMed PubMed Citation Articles by Brawer, M. K.

CA: A Cancer Journal for Clinicians, Vol 49, Issue 5 264-281, Copyright © 1999 by American Cancer Society

ARTICLES

Prostate-specific antigen: current status

M. K. Brawer
Northwest Prostate Institute, Northwest Hospital, Seattle, WA, USA.

Prostate-specific antigen (PSA) is the most important of all tumor markers in that it has significant applications in all aspects of the management of men with prostatic disease. Certainly, the most important utilization of PSA is for the early detection of this most ubiquitous of all human neoplasms. This article reviews the salient features of PSA, with particular emphasis on strategies to improve its utility in the diagnosis of prostate cancer. So-called PSA derivatives--including age-specific PSA, PSA velocity, and PSA density--are discussed. With the recognition of molecular forms of PSA, however, the ratio of free-to-total PSA, and now the complex form of PSA, have been shown to be more specific indicators of the presence of malignancy. Significant public interest and research efforts in prostate cancer have resulted in numerous advances over the past decade. The discovery of PSA and the development of assays to measure it will undoubtedly be recorded as one of the most important advances in the management of men with prostate cancer.

This article has been cited by other articles:

				G.-J. C. M. van den Bemd, J. Krijgsveld, T. M. Luider, A. L. van Rijswijk, J. A. A. Demmers, and G. Jenster Mass Spectrometric Identification of Human Prostate Cancer-derived Proteins in Serum of Xenograft-bearing Mice Mol. Cell. Proteomics, October 1, 2006; 5(10): 1830 - 1839. [Abstract] [Full Text] [PDF]

				G. Tabares, C. M. Radcliffe, S. Barrabes, M. Ramirez, R. N. Aleixandre, W. Hoesel, R. A. Dwek, P. M. Rudd, R. Peracaula, and R. de Llorens Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA Glycobiology, February 1, 2006; 16(2): 132 - 145. [Abstract] [Full Text] [PDF]

				H. G. Welch, L. M. Schwartz, and S. Woloshin Prostate-Specific Antigen Levels in the United States: Implications of Various Definitions for Abnormal J Natl Cancer Inst, August 3, 2005; 97(15): 1132 - 1137. [Abstract] [Full Text] [PDF]

				G. Soletormos, A. Semjonow, P. E.C. Sibley, R. Lamerz, P. H. Petersen, W. Albrecht, P. Bialk, M. Gion, F. Junker, H.-P. Schmid, et al. Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice Clin. Chem., August 1, 2005; 51(8): 1342 - 1351. [Abstract] [Full Text] [PDF]

				E. M. Posadas, F. Simpkins, L. A. Liotta, C. MacDonald, and E. C. Kohn Proteomic analysis for the early detection and rational treatment of cancer--realistic hope? Ann. Onc., January 1, 2005; 16(1): 16 - 22. [Abstract] [Full Text] [PDF]

				R. Peracaula, G. Tabares, L. Royle, D. J. Harvey, R. A. Dwek, P. M. Rudd, and R. de Llorens Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins Glycobiology, June 1, 2003; 13(6): 457 - 470. [Abstract] [Full Text] [PDF]

				S. Oottamasathien and E. D. Crawford Should Routine Screening for Prostate-Specific Antigen Be Recommended? Arch Intern Med, March 24, 2003; 163(6): 661 - 663. [Full Text] [PDF]

				B. E. Sirovich, L. M. Schwartz, and S. Woloshin Screening Men for Prostate and Colorectal Cancer in the United States: Does Practice Reflect the Evidence? JAMA, March 19, 2003; 289(11): 1414 - 1420. [Abstract] [Full Text] [PDF]

				Y.-C. Ou, J.-T. Chen, C.-R. Yang, C.-L. Cheng, H.-C. Ho, J.-L. Ko, and Y.-S. Hsieh Predicting Prostate Specific Antigen Failure after Radical Retropubic Prostatectomy for T1c Prostate Cancer Jpn. J. Clin. Oncol., December 1, 2002; 32(12): 536 - 542. [Abstract] [Full Text] [PDF]

				D Mazhar and J Waxman Prostate cancer Postgrad. Med. J., October 1, 2002; 78(924): 590 - 595. [Abstract] [Full Text] [PDF]

				Y.-C. Ou, J.-T. Chen, C.-R. Yang, C.-L. Cheng, H.-C. Ho, Y.-L. Kao, J.-L. Ko, and Y.-S. Hsieh Preoperative Prediction of Extracapsular Tumor Extension at Radical Retropubic Prostatectomy in Taiwanese Patients with T1c Prostate Cancer Jpn. J. Clin. Oncol., May 1, 2002; 32(5): 172 - 176. [Abstract] [Full Text] [PDF]